MDCX vs. AMGN
MDCX (Medicus Pharma Ltd) and AMGN (Amgen Inc.) are both stocks. Both are in the Healthcare sector — MDCX in Biotechnology, AMGN in Drug Manufacturers - General. Over the past year, MDCX returned -87.08% vs 25.42% for AMGN. At a 0.06 correlation, their price movements are largely independent.
Performance
MDCX vs. AMGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDCX achieves a -77.12% return, which is significantly lower than AMGN's 8.36% return.
MDCX
- 1D
- -6.32%
- 1M
- 5.23%
- YTD
- -77.12%
- 6M
- -82.93%
- 1Y
- -87.08%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
AMGN
- 1D
- 1.15%
- 1M
- 6.38%
- YTD
- 8.36%
- 6M
- 7.51%
- 1Y
- 25.42%
- 3Y*
- 20.11%
- 5Y*
- 11.56%
- 10Y*
- 11.48%
MDCX vs. AMGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
MDCX Medicus Pharma Ltd | -77.12% | -37.04% | -8.30% |
AMGN Amgen Inc. | 8.36% | 29.67% | -11.22% |
Correlation
The correlation between MDCX and AMGN is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Nov 15, 2024 | 0.06 |
Fundamentals
MDCX:
-$1.93
AMGN:
$14.38
MDCX:
$0.00
AMGN:
$37.24B
MDCX:
$0.00
AMGN:
$26.61B
MDCX:
-$36.18M
AMGN:
$17.27B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDCX vs. AMGN — Risk / Return Rank
MDCX
AMGN
MDCX vs. AMGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Medicus Pharma Ltd (MDCX) and Amgen Inc. (AMGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MDCX | AMGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.64 | ||
| Sortino ratioReturn per unit of downside risk | -2.80 | ||
| Omega ratioGain probability vs. loss probability | 0.83 | 1.19 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | -0.95 | 1.54 | -2.49 |
| Martin ratioReturn relative to average drawdown | -1.52 | 3.61 | -5.13 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| MDCX | AMGN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.71 | 0.93 | -1.64 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.49 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.46 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.56 | 0.61 | -1.17 |
Drawdowns
MDCX vs. AMGN - Drawdown Comparison
The maximum MDCX drawdown since its inception was -96.47%, which is greater than AMGN's maximum drawdown of -63.48%. Use the drawdown chart below to compare losses from any high point for MDCX and AMGN.
Loading charts...
Drawdown Indicators
| MDCX | AMGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.47% | -63.48% | -32.99% |
Max Drawdown (1Y)Largest decline over 1 year | -91.91% | -16.57% | -75.34% |
Max Drawdown (3Y)Largest decline over 3 years | — | -22.74% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -24.86% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -24.86% | — |
Current DrawdownCurrent decline from peak | -95.50% | -9.26% | -86.24% |
Average DrawdownAverage peak-to-trough decline | -56.04% | -16.78% | -39.26% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 57.19% | 7.06% | +50.13% |
Volatility
MDCX vs. AMGN - Volatility Comparison
Medicus Pharma Ltd (MDCX) has a higher volatility of 29.13% compared to Amgen Inc. (AMGN) at 6.28%. This indicates that MDCX's price experiences larger fluctuations and is considered to be riskier than AMGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDCX | AMGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.13% | 6.28% | +22.85% |
Volatility (6M)Calculated over the trailing 6-month period | 116.72% | 19.17% | +97.55% |
Volatility (1Y)Calculated over the trailing 1-year period | 123.02% | 27.32% | +95.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 130.67% | 23.88% | +106.79% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 130.67% | 24.81% | +105.86% |
Dividends
MDCX vs. AMGN - Dividend Comparison
MDCX has not paid dividends to shareholders, while AMGN's dividend yield for the trailing twelve months is around 2.80%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMGN Amgen Inc. | 2.80% | 2.91% | 3.45% | 2.96% | 2.95% | 3.13% | 2.78% | 2.41% | 2.71% | 2.65% | 2.74% | 1.95% |
MDCX Medicus Pharma Ltd | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
MDCX vs. AMGN - Financials Comparison
This section allows you to compare key financial metrics between Medicus Pharma Ltd and Amgen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MDCX and AMGN have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MDCX has higher volatility (29.13%) compared to AMGN (6.28%). In terms of maximum drawdown, MDCX dropped -96.47% vs AMGN's -63.48%.
AMGN currently has the higher Sharpe Ratio (0.93 vs -0.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDCX and AMGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer